TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications. 

TCT 2023 | SWEDEHEART, evolución  a 5 años

The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal) compared T-TEER against medical treatment and did not find differences in mortality or CF related hospitalization at 1 year, but did observe improved health status with T-TEER.

The aim of this prospective, multicenter and randomized study was to assess the benefit of T-TEER in health status. 

Health status was measured by the Kansas questionnaire (KCCQ, Kansas City Cardiomyopathy Questionnaire) based on time reference points: at kickoff, 1 month, 6 months and 1 year. 

Read also: TCT 2023 The LIFE-BTK Trial.

A total 350 patients were randomized: 175 to receiving T-TEER and 175 to medical treatment (MT). Mean age was 78, and most patients were women. At 1 month, T-TEER resulted in improved health status and showed continuous improvement at 1 year, vs. MT. Patients undergoing T-TEER saw better survival and good health status at one year, vs MT patients (74,8% vs. 45,9%, p<0,001) with necessary number to treat (NNT) 3.5.

Conclusion

In conclusion, in this study, patients treated with T-TEER experienced improved health status vs patients receiving MT alone, and this improvement was more evident in patients with symptomatic TR. Improved health status was more evident at 1 month and was maintained at 1 year followup. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Health Status after Transcatheter Tricuspid-Valve Repair in Patients with Severe Tricuspid Regurgitation: Results from the TRILUMINATE Pivotal Trial.

Reference: Suzanne V. Arnold, MD MHA et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...